The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 5, 2001, Pages 349-357

  Miyake, Y ^a   Yokota, Koichi ^a   Fujishima, Y ^a   Sukamoto, T ^a  

^a Nippon Organon KK   (Japan)

Author keywords

Bleeding; Dalteparin; Danaparoid; Disseminated intravascular coagulation; Heparin; Platelet aggregation

Indexed keywords

DALTEPARIN; DANAPAROID; HEPARIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; BLEEDING TIME; CHONDROITIN SULFATES; DALTEPARIN; DERMATAN SULFATE; DISEASE MODELS, ANIMAL; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FACTOR XA; HEPARIN; HEPARITIN SULFATE; KINETICS; MALE; PLATELET AGGREGATION; RATS; RATS, WISTAR; RISK ASSESSMENT; THROMBOPLASTIN;

EID: 0034898044     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200107000-00003     Document Type: Article

References (35)

1. Disseminated intravascular coagulation and related syndromes: A clinical review
2. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways
3. Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy
4. The defibrination syndrome: Clinical features and laboratory diagnosis
5. Disseminated intravascular coagulation in pregnancy. The role of heparin therapy
6. Biochemistry of heparin-antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism
7. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans
8. Management of heparin therapy: Controlled prospective trial
9. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - A multicenter co-operative double-blind trial in comparison with heparin
10. Dalteparin: A low-molecular-weight heparin
11. Orgaran (Org 10172): Its pharmacological profile in experimental models
12. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models
13. Anticoagulant profile of low molecular weight heparinoids (KB-101) and its in vivo effects on experimental DIC
14. The effect of danaparoid sodium (danaparoid) on endotoxin-in-duced experimental disseminated intravascular coagulation (DIC) in rats
15. Danaparoid in the prevention of thromboembolic complications
16. Evaluation of clinical effect of danaparoid sodium (KB-101) on disseminated intravascular coagulation (DIC): Double blind comparative study
17. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans
18. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: Evidence that Ro 43-8857 is orally active
19. Effect of KBT-3022, a new diphenylthiazole derivative, on platelet functions
20. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats
21. Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa
22. Clinical phase I study of KB-101: Single and repeated administration studies by subcutaneous injection and intravenous injection
23. Proteolytic activation of human factors IX and x by recombinant human factor VIIa: Effects of calcium, phospholipids, and tissue factor
24. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin
25. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats
26. Effects of low molecular weight heparin (FR-860) on the experimental disseminated intravascular coagulation models
27. Diagnostic uses of the activated partial thromboplastin time and prothrombin time
28. A randomized and blinded comparison of three bleeding time techniques: The Ivy method, and the Simplate II® method in two directions
29. Impairment of primary haemostasis by low molecular weight heparins in rats
30. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats
31. Bleeding effects of unfractionated heparin and low molecular weight heparins in an animal model
32. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time
33. Platelets and blood vessels
34. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro
35. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: Effects of hirudins, heparin, and calcium chelation